Covalon Technologies Ltd. to Exhibit at the Largest Annual Infection Prevention and Control Conference in the World
Covalon will be showcasing its unique line of antimicrobial self-adherent silicone products, including MediClear™ PreOp, the market’s first breathable and transparent antimicrobial self-adherent silicone drape for preoperative skin. Its polyurethane barrier film acts as a protective barrier to isolate a procedural site from external contamination, and its silicone adhesive provides a rapid bactericidal and fungicidal effect against a broad spectrum of microorganisms, averaging a 99.99% reduction after 30 minutes, and preventing their regrowth for up to seven days during wear.1
Covalon’s other ground-breaking infection-fighting products will also be on display, including SurgiClear™, a dual antimicrobial transparent post-operative dressing, and IV Clear™, an antimicrobial clear silicone adhesive securement dressing to cover and protect vascular access devices, both of which are proven to have a synergistic effect against some of the most commonly associated hospital-acquired infection bacteria.2
“APIC 2018 is a great opportunity for Covalon to display our innovative infection prevention products to medical professionals and potential business partners from around the world,” said Brian Pedlar, Chief Executive Officer. “The cost of fighting unwanted infections is a significant burden to health care systems in every country. Our products and technologies were developed to kill bacteria and other pathogens that can lead to infections that hospitals otherwise spend significant amounts to treat and that are responsible for needless deaths every year.”
APIC 2018 features the largest exhibition of leading-edge science and technology dedicated to infection prevention and showcases innovative products and services from more than 270 companies. It is the largest annual gathering of infection prevention specialists from across the United States and around the world.
Visit Covalon at Booth 1547 at APIC 2018 during exhibit hours June 13th to 15th at the Minneapolis Convention Center in Minneapolis, MN, USA.
Covalon Technologies Ltd. researches, develops and commercializes new healthcare technologies that help save lives around the world. Covalon's patented technologies, products and services address the advanced healthcare needs of medical device companies, healthcare providers and individual consumers. Covalon's technologies are used to prevent, detect and manage medical conditions in specialty areas such as wound care, tissue repair, infection control, disease management, medical device coatings and biocompatibility. To learn more about Covalon, visit our website at www.covalon.com
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This news release contains forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements are often, but not always, identified by the use of words such as "seek", "anticipate", "plan, "estimate", "expect", "intend" and statements that an event or result "may", "will", "should", "could" or "might" occur or be achieved and other similar expressions. These forward-looking statements involve risk and uncertainties, including the difficulty in predicting product approvals, acceptance of and demands for new products, the impact of the products and pricing strategies of competitors, delays in developing and launching new products, the regulatory environment, fluctuations in operating results and other risks, any of which could cause results, performance, or achievements to differ materially from the results discussed or implied in the forward-looking statements. Many risks are inherent in the industry; others are more specific to the Company. Investors should consult the Company's ongoing quarterly filings for additional information on risks and uncertainties relating to these forward-looking statements. Investors should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update or alter any forward-looking statements whether as a result of new information, further events or otherwise.
1 Covalon Technologies Ltd. Data on file.
2 A Laboratory Study of the Synergistic Effect of Chlorhexidine and Silver, Blom, Kristina Werthen, Maria et al. American Journal of Infection Control , Volume 43 , Issue 6 , S22
Source: Covalon Technologies Ltd.